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1. Introduction 
Hypophosphatasia (HPP) is an inherited disorder characterized by defective mineralization 
of the bone and low activity of alkaline phosphatase (ALP; EC 3.1.3.1) (Mornet, 2008). 
Screening for mutations in the ALPL gene allows genetic counseling and prenatal diagnosis 
of the disease in families with severe forms of HPP. 
2. Hypophosphatasia 
HPP is a clinically heterogeneous disease and classified into at least six forms according to 
severity and age of onset: perinatal (lethal), perinatal (benign), infantile (MIM [Mendelian 
Inheritance in Man] # 241500), childhood (MIM# 241510), adult (MIM# 146300), and 
odontohypophosphatasia (Mornet, 2008) (Table 1). All forms of HPP display reduced activity 
of unfractionated serum ALP and the presence of either one or two pathologic mutations in 
the liver/bone/kidney alkaline phosphatase gene (ALPL, MIM# 171760), the gene encoding 
ALP, the tissue-nonspecific isozyme (TNSALP). There is no curative treatment for HPP to date.  
2.1 ALPL gene 
ALPL is the only gene known to be associated with HPP. ALPL consists of 12 exons: 11 
coding exons and one untranslated exon. More than250 ALPL mutations have been 
described in persons from North America, Japan, and Europe (The Tissue Nonspecific 
Alkaline Phosphatase Gene Mutations Database). HPP is frequently caused by p.E191K and 
p.D378V in Caucasian, whereas p.F327L and c.1559delT are more common in Japanese(the 
first nucleotide (+1) corresponds to the A of the ATG initiation codon using the ALPL cDNA 
number of the standard nomenclature). This variety of mutations in ALPL results in highly 
variable clinical expression and in a great number of compound heterozygous genotypes. 
2.2 Perinatal (lethal) form of hypophosphatasia 
The perinatal (lethal) form of HPP (pl-HPP) is the most severe HPP with an autosomal 
recessive mode of inheritance (Gehring et al., 1999) In the lethal perinatal form, the patients 
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show markedly impaired mineralization in utero (Fig.1). Pregnancies may end in stillbirth. 
Some infants survive a few days with pulmonary complication due to hypoplastic lungs and 
rachitic deformities of the chest. Hypercalcemia is common and may be associated with 
apnea or seizures.  
 
Type Inheritance MIM Symptoms 
Perinatal  (lethal) AR Hypomineralization, 
osteochondral spurs 
Perinatal  (benign) AR or AD Long-bone bowing, benign 
postnatal course 
Infantile  AR 241500 Craniosynostosis, 
Hypomineralization, rachitic ribs, 
hypercalciuria, Premature loss, 
deciduous teeth
Childhood AR or AD 241510 Short stature, skeletal deformity, 
bone pain/fractures, Premature 
loss, deciduous teeth
Adult  AR or AD 146300 Stress fractures: metatarsal, tibia; 
chondrocalcinosis 
Odontohypophosphatasia AR or AD Exfoliation (incisors), dental caries 
, Alveolar bone loss
Table 1. Clinical Features of Hypophosphatasia by Type. AD; autosomal dominant, AR; 
autosomal recessive 
 
Fig. 1. Ultrasonography examination at 19 weeks’ gestation of pl-HPP fetus 
The upper limb(A) femur(B) at 19 weeks’ gestation was shortened with no evidence of 
fractures. The cranium(C) at 19 weeks’ gestation was thin with marked hypomineralization. 
pl-HPP is more common in Japan than in other countries (Satoh et al. 2009). Parents of pl-
HPP are heterozygous carriers of ALPL mutations. They show no clinical symptoms, but 
have reduced serum ALP activity and increased urinary phosphoethanolamine (PEA).  
2.3 c.1559delT in ALPL, a common mutation resulting in the perinatal (lethal) form of 
hypophosphatasia in Japan 
c.1559delT in ALPL is a common mutation resulting in pl-HPP in Japan and has only been 
found in Japanese to date (Orimo et al., 2002; Michigami et al., 2005). Symptoms caused by 
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deletions and insertions of nucleotides that change the reading frame will be highly 
deleterious. Some patients with pl-HPP are homozygous for c.1559delT, with parents who 
are heterozygous carriers for the mutation but with no evidence of consanguinity (Fig. 2) 
(Sawai et al. 2003). Patients who are homozygous for the c.1559delT mutation differed in the 
severity of HPP, including both their symptoms and serum ALP activity. In the c.1559delT 
mutation, the symptom in HPP of homozygous mutation is responsible for a severe 
phenotype, but that of compound hetero varies from severe to mild that depends on 
mutation position in other allele. 
 
Fig. 2. Direct sequencing results around 1559delT in ALPL from a pl-HPP patient both 
parents, and healthy control. The sequence of the parents could not be determined in 
progress at cDNA number 1559 of the ALPL and these results indicate both parents were 
heterogenous carriers for 1559delT. The sequence of the pl-HPP patient could be 
determined in progress containing the deletion of T at nucleotide 1559, which was 
different from that of a healthy control and indicates that the fetus is homozygous for a 
1559delT of the ALPL. 
c.1559delT, a deletion of T at 1559, which caused a frameshift downstream from leucine 
(Leu) at codon 503, resulted in the elimination of the termination codon at 508 and the 
addition of 80 amino acid residues at the C-terminus. The mutant protein caused by 
1559delT formed an aggregate, was polyubiquitinated, and was then degraded in the 
proteome (Komaru et al., 2005), thus allowing us to directly correlate the phenotype 
(perinatal type) and the genotype (1559delT). 
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The c.1559delT carrier frequency is 1/480 (95% confidence interval, 1/1,562-1/284) in Japanese 
(Watanabe et al. 2011). This indicates that approximately 1 in 900,000 individuals to have pl-
HPP caused by a homozygous c.1559delT mutation. The majority of c.1559delT carriers had 
normal values of HPP biochemical markers, such as serum ALP and urine PEA. The only way 
to reliably detect the pl-HPP carriers is to perform the ALPL mutation analysis. 
2.4 Prenatal diagnosis for perinatal (lethal) form of hypophosphatasia 
pl-HPP has been diagnosed in utero by ultrasonography performed with careful attention to 
marked hypomineralization of the limbs and the skull (Fig.1) (Tongsong & Pongsatha, 2000). 
The differential diagnosis of HPP depends on the age at which the diagnosis is considered. 
Ultrasonography examination in prenatal stage may lead to a consideration of osteogenesis 
imperfecta type II, campomelic dysplasia, and chondrodysplasias with defects in bone 
mineralization, as well as pl-HPP. Experienced sonographers usually have little difficulty in 
distinguishing among these disorders. However, pl-HPP is occasionally not diagnosed with 
sonographic examination in the first trimester because incomplete ossification is a normal 
finding at this stage of development (Zankl, 2008).  
Prenatal assessment for pregnancies at increased risk of severe HPP by mutation analysis is 
possible if two HPP causing ALPL mutations of an affected family member are identified 
(Watanabe et al., 2007). Most of pl-HPPs are related to c.1559delT in Japan (Watanabe et al., 
2011), but to usually compound heterozygotes, carrying two distinct mutations in US and 
France (Simon-Bouy et al., 2008). In Japan,screeing of c.1559delT is important to diagnose pl-
HPPs. In out of Japan, mutations occur throughout the entire gene without hot spots. To detect 
different mutations, all exon screening of ALPL is needed. In prenatal genetic diagnosis, fetal 
genomic DNA was extracted from chorionic villus at approximately ten to 12 weeks' gestation 
or cultured cells of amniotic fluid at approximately 15 to 18 weeks' gestation. 
A prenatal genetic diagnosis for HPP gives a couple important information about the fetus. 
Prenatal genetic diagnosis for HPP in combination with ultrasonography is thus considered 
useful for confirming a diagnosis of HPP, which presents with a wide variety of phenotypes. 
2.5 Genetic counseling for perinatal (lethal) form of hypophosphatasia 
Genetic counseling for pl-HPP has two situations, family with an affected first child (index 
case) or fortuitous prenatal skeletal dysplasia in a family without history of HP (no index 
case) (Fig. 3) (Simon-Bouy et al., 2008). First, a couple with an index case with recessive form 
of pl-HPP will have in subsequent pregnancies affected children similar to the index case 
with a 25% chance of recurrence. However, the severity of symptoms in HPP may differ 
from one child to another even in the same mutation (Nakamura-Utsunomiya, 2010). 
Second, in pl-HPP, pregnancies with clinical symptoms could be detected by ultrasound 
with no familial history of pl-HPP (no index case). The screening for c.1559delT in ALPL 
may be useful for diagnosis of pl-HPP in Japanese. Detection of 1559delT mutation confirms 
the diagnosis of severe HPP, and an attempt to predict the severity of the disease. Postnatal 
molecular genetic analysis using the cord tissue can provide a diagnosis of pl-HPP allows 
time for parental counseling and delivery planning. In addition, Enzyme replacement 
therapy (Millán JL et al., 2008) and gene therapy (Yamamoto et al., 2011) will be certainly the 
most promising challenge. Confirmation of the diagnosis of HPP by ALPL genetic testing 
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will be indispensable before starting the treatment, and perhaps the characterization of the 
mutations will orient and personalize the treatment in future.  
 
Fig. 3. Pedigree examples of two situations in genetic counseling for pl-HPP: A) family with 
an affected first child (index case) or B) fortuitous prenatal skeletal dysplasia in a family 
without history of HP (no index case) 
A prenatal diagnosis should be provided in a supportive, noncoercive atmosphere that 
allows the couple to make informed choices regarding what is are best for them in view of 
their values and parenting goals. Genetic counseling is particularly important before 
prenatal diagnosis to enable parents to make an informed choice. Counseling before testing 
makes counseling after testing (for those with an affected fetus) less difficult because 
prospective parents are better prepared. Careful counseling regarding if and how to inform 
the parents about the child can help to overcome this potential problem. A prenatal genetic 
diagnosis may also help the professional team to prepare for a difficult delivery.  
3. Conclusion 
To diagnose pl-HPP in prenatal stage, collaborations between obstetricians and clinical 
geneticists are important and could provide support for parents of prenatal patients 
suspected of having skeletal dysplasia. 
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